drugset / Trial / NCT01411241

Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers

NCT01411241

Phase 3 Completed 720 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The aim of the study was to assess whether the second CYD dengue vaccination could be administered concomitantly with the booster vaccination of a pediatric combination vaccine (Pentaxim™) during the same day visit but in 2 different sites of administration. Primary Objective: * To demonstrate the non-inferiority of the antibody response against all antigens (diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b (Hib)) in participants receiving one booster dose of Pentaxim™ vaccine administered concomitantly with the second dose of CYD dengue vaccine compared to participants receiving one booster dose of Pentaxim™ vaccine administered concomitantly with placebo. Secondary Objectives: * To describe the safety of Pentaxim™ vaccine administered concomitantly with the second dose of CYD dengue vaccine, or administered concomitantly with placebo. * To describe the safety of the CYD dengue vaccine after the second dose of CYD dengue vaccine administered concomitantly with Pentaxim™ vaccine (at Visit 05) or administered alone (at Visit 06). * To describe the safety of the CYD dengue vaccine in all participants after each dose. * To describe the antibody response to each dengue virus serotype (post-Dose 2 and post-Dose 3) after the second dose of CYD dengue vaccine administered concomitantly with Pentaxim vaccine (at Visit 05) or administered alone (at Visit 06). * To describe the antibody response to each dengue virus serotype post-Dose 2 and post-Dose 3.

Timeline

Start
2011-07-18
Primary completion
2014-02-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject CYD Dengue Vaccine Vaccine 0.5 ml Subcutaneous
Subject DTaP IPV//Hib vaccine Vaccine 0.5 ml Intramuscular
Background Measles, mumps, and rubella vaccine Vaccine 0.5 ml Subcutaneous
Background Prevnar 13 Vaccine 0.5 ml Intramuscular